logo
Twitter
Discord
Email
logo
Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

NASDAQ•HRMY
CEO: Mr. Jeffrey S. Aronin
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-08-19
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Contact Information
630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, 19462, United States
484-539-9800
www.harmonybiosciences.com
Market Cap
$2.09B
P/E (TTM)
11.4
38.2
Dividend Yield
--
52W High
$40.93
52W Low
$25.52
52W Range
69%
Rank37Top 34.1%
4.4
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 4.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$239.46M+28.71%
4-Quarter Trend

EPS

$0.88+8.64%
4-Quarter Trend

FCF

$108.66M+54.14%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Net product revenue reached $624.7M for nine months, increasing 21.7% versus prior year periods.
Net Income Significantly Rises Nine-month net income $136.2M, significantly up from $96.0M reported for the same period in 2024.
Cash Position Robust Cash, equivalents, and investments total $778.4M as of September 30, 2025, supporting operations.
Pipeline Milestone Achieved Achieved ZYN002 clinical milestone triggering $15.0M payment to contingent value rights holders in Q4 2025.

Risk Factors

R&D Spending Accelerates Nine-month R&D expenses rose 25.6% to $139.7M, driven by $30.0M in acquired IPR&D charges.
High Customer Concentration Three customers accounted for 100% of gross accounts receivable as of September 30, 2025.
Generic Litigation Settlements Multiple ANDA litigations pending; settlements grant generic license for WAKIX starting January 2030.
Single API Supplier Risk Company relies on single API supplier for WAKIX and single API suppliers for all potential candidates.

Outlook

WAKIX Label Expansion Pursuing pediatric exclusivity; resubmitting sNDA for pediatric cataplexy indication in Q3 2025.
Pipeline Advancement Focus Advancing Pitolisant GR/HD clinical studies; reviewing ZYN002 RECONNECT trial results for next steps.
Liquidity Runway Secured Existing capital resources expected to fund operational liquidity needs for at least the next twelve months.
New Asset Development Continuing development for EPX-100 Phase 3 trials and BP1.15205 pre-clinical program advancement.

Peer Comparison

Revenue (TTM)

Novavax, Inc.NVAX
$1.06B
+20.3%
Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
Immunocore Holdings plcIMCR
$379.59M
+27.8%

Gross Margin (Latest Quarter)

Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp
Immunocore Holdings plcIMCR
99.5%
+0.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EWTX$2.90B-18.4-30.9%0.7%
VRDN$2.70B-9.0-52.6%4.1%
RCUS$2.19B-6.7-69.8%11.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.0%
Steady Growth
4Q Net Income CAGR
0.9%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:$0.81
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $239.46M+28.7%
    |
    EPS: $0.88+8.6%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $200.49M+16.0%
    |
    EPS: $0.69+245.0%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $184.73M+19.5%
    |
    EPS: $0.79+16.2%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|
    Revenue: $714.73M+22.8%
    |
    EPS: $2.56+18.0%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 29, 2024|
    Revenue: $186.04M+16.1%
    |
    EPS: $0.81+26.6%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $172.81M+28.8%
    |
    EPS: $0.20-64.9%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 30, 2024|
    Revenue: $154.62M+29.8%
    |
    EPS: $0.68+38.8%
    Beat

  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $582.02M+32.9%
    |
    EPS: $2.17-29.3%
    Beat